Patient Portal

Nancy Lee Bartlett, MD

Professor, Medicine
Division of Oncology
Koman Chair in Medical Oncology

Specialty Areas

Medical Oncology
Oncology
Hematologic Malignancies
Lymphoma

Board Certifications

Internal Medicine
Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Non-Hodgkin's and Hodgkin's lymphoma, chronic lymphocytic leukemia, hematologic malignancies

  • Maps & Directions
  • Education
  • Publication & Research

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: 314-747-1171
Fax: 314-747-5123

Education

Education

Fellowship: Medical Oncology, Stanford University, California 1993
Chief Residency: Medicine, University of California, San Francisco, California 1990
Residency: Medicine, University of California, San Francisco, California 1989
Medical Degree: Washington University School of Medicine, St. Louis, Missouri 1986
M.S.: Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 1979
B.A.: Chemical Engineering, Stanford University, California 1978

Publication & Research

Publication & Research

Rituximab with ABVD vs ABVD for advanced stage high-risk classical Hodgkin lymphoma: a randomized phase II study.
Strati P, Fanale M, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ
Haematologica. 2018 Sep 6; pii: haematol.2018.199844. doi: 10.3324/haematol.2018.199844.

PMID:
    30190343
    [PubMed - as supplied by publisher]
Related citations


Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA, RELEVANCE Trial Investigators.
N Engl J Med. 2018 Sep 6; 379(10)934-947. doi: 10.1056/NEJMoa1805104.

PMID:
    30184451
    [PubMed - in process]
Related citations


Chimeric Antigen Receptor T-Cell Therapy.
Ogba N, Arwood NM, Bartlett NL, Bloom M, Brown P, Brown C, Budde EL, Carlson R, Farnia S, Fry TJ, Garber M, Gardner RA, Gurschick L, Kropf P, Reitan JJ, Sauter C, Shah B, Shpall EJ, Rosen ST
J Natl Compr Canc Netw. 2018 Sep; 16(9)1092-1106. doi: 10.6004/jnccn.2018.0073.

PMID:
    30181421
    [PubMed - in process]
Related citations


In Situ Vaccination with a TLR 9 Agonist and Local Low Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.
Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Long SR, Hoppe RT, Janssen RS, Candia AF, Coffman RL, Levy R
Cancer Discov. 2018 Aug 28; pii: CD-18-0743. doi: 10.1158/2159-8290.CD-18-0743.

PMID:
    30154192
    [PubMed - as supplied by publisher]
Related citations


CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL
Blood. 2018 Sep 6; 132(10)1013-1021. doi: 10.1182/blood-2018-01-827246.

PMID:
    30049811
    [PubMed - in process]
Related citations


Formulating a Treatment Plan in Suspected Lymphoma: Ultrasound-Guided Core Needle Biopsy Versus Core Needle Biopsy and Fine-Needle Aspiration of Peripheral Lymph Nodes.
Drylewicz MR, Watkins MP, Shetty AS, Lin MF, Salter A, Bartlett NL, Middleton WD, Yano M
J Ultrasound Med. 2018 Jul 25; doi: 10.1002/jum.14724.

PMID:
    30043431
    [PubMed - as supplied by publisher]
Related citations


CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
Watkins MP, Bartlett NL
Expert Opin Investig Drugs. 2018 Jul; 27(7)601-611. doi: 10.1080/13543784.2018.1492549.

PMID:
    29940805
    [PubMed - indexed for MEDLINE]
Related citations


Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P
Haematologica. 2018 Sep; 103(9)1502-1510. doi: 10.3324/haematol.2018.192328.

PMID:
    29880603
    [PubMed - in process]
Related citations


Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM
N Engl J Med. 2018 Apr 12; 378(15)1396-1407. doi: 10.1056/NEJMoa1801445.

PMID:
    29641966
    [PubMed - indexed for MEDLINE]
Related citations


Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Uttarwar M, Lee SY, Ren H, Kennedy DA, Shustov AR
Blood. 2018 May 10; 131(19)2120-2124. doi: 10.1182/blood-2017-12-821009.

PMID:
    29507077
    [PubMed - in process]
Related citations


Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.
Mehta-Shah N, Bartlett NL
Blood. 2018 Apr 12; 131(15)1698-1703. doi: 10.1182/blood-2017-09-772681.

PMID:
    29500171
    [PubMed - in process]
Related citations


SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma.
Watkins MP, Fanale MA, Bartlett NL
Clin Lymphoma Myeloma Leuk. 2018 Feb; 18(2)81-90. doi: 10.1016/j.clml.2018.01.001.

PMID:
    29366607
    [PubMed - in process]
Related citations


Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH
Blood. 2018 Mar 15; 131(11)1183-1194. doi: 10.1182/blood-2017-10-811224.

PMID:
    29229594
    [PubMed - in process]
Related citations


Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY
N Engl J Med. 2017 Dec 28; 377(26)2531-2544. doi: 10.1056/NEJMoa1707447.

PMID:
    29226797
    [PubMed - indexed for MEDLINE]
Related citations


Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J, ECHELON-1 Study Group.
N Engl J Med. 2018 Jan 25; 378(4)331-344. doi: 10.1056/NEJMoa1708984.

PMID:
    29224502
    [PubMed - indexed for MEDLINE]
Related citations


Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.
Bartlett NL
Hematology Am Soc Hematol Educ Program. 2017 Dec 8; 2017(1)317-323. doi: 10.1182/asheducation-2017.1.317.

PMID:
    29222273
    [PubMed - indexed for MEDLINE]
Related citations


Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP
Br J Haematol. 2017 Dec; 179(5)739-747. doi: 10.1111/bjh.14951.

PMID:
    29082519
    [PubMed - indexed for MEDLINE]
Related citations


Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, Thye LS, Anderson DM, Krysiak K, Ramirez C, Qi J, Siegel BA, Griffith M, Griffith OL, Gomez F, Fehniger TA
Blood. 2018 Jan 11; 131(2)182-190. doi: 10.1182/blood-2017-09-804641.

PMID:
    29074501
    [PubMed - in process]
Related citations


Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A
Blood. 2017 Dec 21; 130(25)2709-2717. doi: 10.1182/blood-2017-05-780049.

PMID:
    28974506
    [PubMed - indexed for MEDLINE]
Related citations


A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).
Martin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, Hsi ED, Ruan J, Smith SE, Leonard JP, Cheson BD
Ann Oncol. 2017 Nov 1; 28(11)2806-2812. doi: 10.1093/annonc/mdx496.

PMID:
    28945884
    [PubMed - indexed for MEDLINE]
Related citations